Skip to main content
SpringerLink
Log in

Onkologika

  • Chapter
Arzneiverordnungs-Report 2015

  • 1938 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Al-SalehK,QuintonC,EllisPM(2012):Roleofpemetrexedinadvancednon-small-celllungcancer:meta-analysisofrandomizedcontrolledtrials,withhistologysubgroupanalysis.CurrOncol19:e9–e15

    Google Scholar 

  • AndreT,BoniC,NavarroM,TaberneroJ,HickishT,TophamC,BonettiA,ClinganP,BridgewaterJ,RiveraF,deGramontA(2009):Improvedoverallsurvivalwithoxaliplatin,fluorouracil,andleucovorinasadjuvanttreatmentinstageIIorIIIcoloncancerintheMOSAICtrial.JClinOncol27:3109–3116

    Article  CAS  Google Scholar 

  • ApperleyJF(2015):Chronicmyeloidleukaemia.Lancet385:1447–1459

    Article  PubMed  Google Scholar 

  • BarbuiT,FinazziMC,FinazziG(2012):Front-linetherapyinpolycythemiaveraandessentialthrombocythemia.BloodRev26:205–211

    CAS  Google Scholar 

  • BeerPA,ErberWN,CampbellPJ,GreenAR(2011):HowItreatessentialthrombocythemia.Blood117:1472–1482

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • BeerTM,ArmstrongAJ,RathkopfDE,LoriotY,SternbergCN,HiganoCS,IversenP,BhattacharyaS,CarlesJ,ChowdhuryS,DavisID,deBonoJS,EvansCP,FizaziK,JoshuaAM,KimCS,KimuraG,MainwaringP,MansbachH,MillerK,NoonbergSB,PeraboF,PhungD,SaadF,ScherHI,TaplinME,VennerPM,TombalB;PREVAILInvestigators(2014):Enzalutamideinmetastaticprostatecancerbeforechemotherapy.NEnglJMed371:424–433

    Article  Google Scholar 

  • BeyerJ,AlbersP,AltenaR,AparicioJetal(2013):Maintainingsuccess,reducingtreatmentburden,focusingonsurvivorship:highlightsfromthethirdEuropeanconsensusconferenceondiagnosisandtreatmentofgerm-cellcancer.AnnOncol24:878–888

    CAS  Google Scholar 

  • BursteinHJ,TeminS,AndersonH,BuchholzTA,DavidsonNE,GelmonKE,GiordanoSH,HudisCA,RowdenD,SolkyAJ,StearnsV,WinerEP,GriggsJJ(2014):Adjuvantendocrinetherapyforwomenwithhormonereceptor-positivebreastcancer:AmericanSocietyofClinicalOncologyclinicalpracticeguidelinefocusedupdate.JClinOncol32:2255–2269

    Article  Google Scholar 

  • BundesministeriumfürGesundheit(2014):BekanntmachungeinesBeschlussesdesGemeinsamenBundesausschussesübereineÄnderungderArzneimittel-Richtlinie(AM-RL):AnlageXII-BeschlüsseüberdieNutzenbewertungvonArzneimittelnmitneuenWirkstoffennach§35adesFünftenBuchesSozialgesetzbuch(SGBV),Ruxolitinibvom6.November2014,veröffentlichtMontag,15.Dezember2014,BAnzAT15.12.2014B–4

    Google Scholar 

  • ByrdJC,JonesJJ,WoyachJA,JohnsonAJ,FlynnJM(2014):EnteringtheEraofTargetedTherapyforChronicLymphocyticLeukemia:ImpactonthePracticingClinician.JClinOncol32:3039–3047

    Article  CAS  Google Scholar 

  • ChesonBD,RummelMJ(2009):Bendamustine:rebirthofanolddrug.JClinOncol27:1492–1501

    Article  CAS  Google Scholar 

  • CoiffierB,LepageE,BriereJ,HerbrechtR,TillyH,BouabdallahR,MorelP,VanDenNesteE,

    Google Scholar 

  • SallesG,GaulardP,ReyesF,LederlinP,GisselbrechtC(2002):CHOPchemotherapyplusrituximabcomparedwithCHOPaloneinelderlypatientswithdiffuselarge-B-celllymphoma.NEnglJMed346:235–242

    Article  Google Scholar 

  • CortesJ,O'ShaughnessyJ,LoeschD,BlumJL,VahdatLT,PetrakovaK,CholletP,ManikasA,DierasV,DelozierT,VladimirovV,CardosoF,KohH,BougnouxP,DutcusCE,SeegobinS,

    Google Scholar 

  • MirD,MenesesN,WandersJ,TwelvesC;EMBRACE(EisaiMetastaticBreastCancerStudyAssessingPhysician'sChoiceVersusE7389)investigators(2011):Eribulinmonotherapyversustreatmentofphysician'schoiceinpatientswithmetastaticbreastcancer(EMBRACE):aphase3open-labelrandomisedstudy.Lancet377:914–923

    Google Scholar 

  • CunninghamD,HumbletY,SienaS,KhayatD,BleibergH,SantoroAetal.(2004):ArandomisedcomparisonofcetuximabmonotherapyandcetuximabplusIrinotecaninirinotecan-refractorymetastaticcolorectalcancer.NEnglJMed351:337–345

    Article  CAS  Google Scholar 

  • CuzickJ,SestakI,BaumM,BuzdarA,HowellA,DowsettM,ForbesJF;ATAC/LATTEinvestigators(2010):Effectofanastrozoleandtamoxifenasadjuvanttreatmentforearly-stagebreastcancer:10-yearanalysisoftheATACtrial.LancetOncol11:1135–1141

    CAS  Google Scholar 

  • DeBonoJS,OudardS,OzgurogluM;TROPICInvestigators,(2010):Prednisonepluscabazitaxelormitoxantroneformetastaticcastration-resistantprostatecancerprogressingafterdocetaxeltreatment:arandomisedopen-labeltrial.Lancet376:1147–1154

    Google Scholar 

  • DeVitaVT,RosenbergSA(2012):Twohundredyearsofcancerresearch.NEnglJMed366:2207–2214

    Article  CAS  Google Scholar 

  • DiLeoA,JerusalemG,PetruzelkaL,TorresR,BondarenkoIN,KhasanovR,VerhoevenD,PedriniJL,SmirnovaI,LichinitserMR,PendergrassK,GarnettS,LindemannJP,SapunarF,MartinM(2010):ResultsoftheCONFIRMphaseIIItrialcomparingfulvestrant250mgwithfulves-trant500mginpostmenopausalwomenwithestrogenreceptor-positiveadvancedbreastcancer.JClinOncol28:4594–4600

    Article  CAS  Google Scholar 

  • DouillardJY,SienaS,CassidyJ,TaberneroJ,BurkesR,BarugelM,HumbletY,BodokyG,

    Google Scholar 

  • CunninghamD,JassemJ,RiveraF,KocakovaI,RuffP,Bfasinska-MorawiecM,SmakalM,CanonJL,RotherM,OlinerKS,WolfM,GansertJ(2010):.Randomized,phaseIIItrialofpanitumumabwithinfusionalfluorouracil,leucovorin,andoxaliplatin(FOLFOX4)versusFOLFOX4aloneasfirst-linetreatmentinpatientswithpreviouslyuntreatedmetastaticcolorectalcancer:thePRIMEstudy.JClinOncol28:4697–4705

    Google Scholar 

  • EarlyBreastCancerTrialists'CollaborativeGroup(EBCTCG)(2005):Effectsofchemotherapyandhormonaltherapyforearlybreastcanceronrecurrenceand15-yearsurvival:anoverviewoftherandomisedtrials.Lancet365:1687–1717

    Article  Google Scholar 

  • ErnstE,SchmidtK,Steuer-VogtMK(2003):Mistletoeforcancer?Asystematicreviewofrandomisedclinicaltrials.IntJCancer107:262–267

    CAS  Google Scholar 

  • EstlinEJ(2001):Continuingtherapyforchildhoodacutelymphoblasticleukaemia:clinicalandcellularpharmacologyofmethotrexate,6-mercaptopurineand6-thioguanine.CancerTreatRev27:351–363

    CAS  Google Scholar 

  • FenauxP,MuftiGJ,Hellstrom-LindbergE,SantiniV,FinelliC,GiagounidisA,SchochR,GattermannN,SanzG,ListA,GoreSD,SeymourJF,BennettJM,ByrdJ,BackstromJ,Zimmerman

    Google Scholar 

  • L,McKenzieD,BeachC,SilvermanLR;InternationalVidazaHigh-RiskMDSSurvivalStudyGroup(2009):Efficacyofazacitidinecomparedwiththatofconventionalcareregimensinthetreatmentofhigher-riskmyelodysplasticsyndromes:arandomised,open-label,phaseIIIstudy.LancetOncol10:223–232

    Google Scholar 

  • Figueroa-MagalhäesMC,JelovacD,ConnollyRM,WolffAC(2014):TreatmentofHER2-positivebreastcancer.Breast23:128–136

    Article  PubMed Central  PubMed  Google Scholar 

  • FoodandDrugAdministration(2011):FDACommissionerremovesbreastcancerindicationfromavastinlabel.Internet:http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/ucm279485.htm

  • Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006): Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743

    Article  CAS  PubMed  Google Scholar 

  • Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group (2013): Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 303–312

    Article  Google Scholar 

  • Harris M (2004): Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292–302

    Article  CAS  PubMed  Google Scholar 

  • Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005): Hydroxyurea compared with anagre- lide in high-risk essential thrombocythemia. N Engl J Med 353: 33–45

    Google Scholar 

  • Heinemann V, Haas M, Boeck S (2012): Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 38: 843–853

    Article  CAS  PubMed  Google Scholar 

  • Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR,

    Google Scholar 

  • Vergote I, Erikstein B, Webster A, Morris C (2002): Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing pro- gressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403

    Article  PubMed  Google Scholar 

  • Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004): Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004): Bevacizu- mab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Jang S, Atkins MB (2013): Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 14: e60–69

    Article  Google Scholar 

  • Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014): Ovarian cancer. Lancet 384: 1376–1388

    Article  PubMed  Google Scholar 

  • Khasraw M, Bell R, Dang C (2012): Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21: 142–149

    Article  PubMed  Google Scholar 

  • Krämer I (2010): Zytostatikaherstellung in der Apotheke. Pharm Unserer Zeit 38: 280–287

    Article  Google Scholar 

  • Lecavalier-Barsoum M, Quon H, Abdulkarim B (2014): Adjuvant treatment of anaplastic oligo- dendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. 2014 May 15; 5: CD00710–4

    Google Scholar 

  • Macedo LT, da Costa Lima AB, Sasse AD (2012): Addition of bevacizumab to first-line chemo- therapy in advanced colorectal cancer: a systematic review and meta-analysis, with em- phasis on chemotherapy subgroups. BMC Cancer 12:8–9. doi: 10.1186/1471-2407-12-89

    Article  Google Scholar 

  • Mahon FX (2015): Discontinuation of tyrosine kinase therapy in CML. Ann Hematol 94 Suppl 2: S187–193

    Google Scholar 

  • Mailankody S, Prasad V (2015): Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncol 1: 539–540

    Article  PubMed  Google Scholar 

  • Martf-Carvajal AJ, Anand V, Sola I (2015): Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database Syst Rev. 2015 Apr 10; 4: CD01029–8

    Google Scholar 

  • Meyerhardt JA, Mayer RJ (2005): Systemic therapy for colorectal cancer. N Engl J Med 352: 476–487

    Article  CAS  PubMed  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009): Gefitinib or carboplatin-paclitaxel in pulmonary adenocar- cinoma. N Engl J Med 361: 947–957

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013): Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722–731

    Article  CAS  PubMed  Google Scholar 

  • Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I (2012): Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23: 30732–2

    Google Scholar 

  • National Institute for Health and Clinical Excellence (NICE) (2011): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. Internet: guidance. nice.org.uk/TA214/Guidance/pdf/English

    Google Scholar 

  • National Institute of Health and Clinical Excellence (2014): Prostate cancer. Diagnosis and treatment. Issued: January 2014, NICE clinical guideline 175. Internet: http://www.nice.org. uk/guidance/cg175/resources/nice-diagnosing-and-treating-prostate-cancer

  • Navarra P, Preziosi P (1999): Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29: 249–255

    Article  CAS  PubMed  Google Scholar 

  • O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group (2004): Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440–449

    Article  Google Scholar 

  • Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Di- mery I, Webster A, Morris C, Elledge R, Buzdar A (2002): A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20: 3386–3395

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Mina R (2013): Management of older adults with multiple myeloma. Blood Rev 27:133–142

    Article  CAS  PubMed  Google Scholar 

  • Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N (2014): Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744–3752

    Article  CAS  PubMed  Google Scholar 

  • Pizzolato JF, Saltz LB (2003): The camptothecins. Lancet 361: 2235–2242

    Article  CAS  PubMed  Google Scholar 

  • Pox C, Schmiegel W, Reinacher-Schick A (2012): Kolorektales Karzinom - Was gibt's Neues? Dtsch med Wochenschr 137: 2577–2580

    Google Scholar 

  • Rafiyan MR, Jäger E (2013): Medikamentöse Behandlung des metastasierten Nierenzellkarzinoms. Dtsch Med Wochenschr 138: 1567–1570

    Article  CAS  PubMed  Google Scholar 

  • Ranpura V, Hapani S, Wu S (2011): Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487–494

    Article  CAS  PubMed  Google Scholar 

  • Röllig C, Knop S, Bornhäuser M (2015): Multiple myeloma. Lancet 385: 2197–2208

    Article  PubMed  Google Scholar 

  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA–302

    Google Scholar 

  • Investigators (2013): Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138–148

    Article  Google Scholar 

  • Saltz LB, Clarke S, Dfaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008): Bevacizumab in combination with oxalipla- tin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013–2019

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators (2012): Increased survival with en- zalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187–1197

    Article  CAS  PubMed  Google Scholar 

  • Shankland KR, Armitage JO, Hancock BW (2012): Non-Hodgkin lymphoma. Lancet 380: 848–857

    Article  PubMed  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D,

    Google Scholar 

  • Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabärbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group (2005): Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

    Article  PubMed  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001): Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  CAS  PubMed  Google Scholar 

  • Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ (2014): Cytotoxic chemotherapy in the contemporary management of metastatic prostate cancer. BJU Int 116: 17–29

    Article  PubMed  Google Scholar 

  • Stilgenbauer S, Hallek M (2013): Chronische lymphatische Leukämie. Therapie und genetisches Risikoprofil. Internist 54:164–170

    Article  CAS  PubMed  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D,

    Google Scholar 

  • Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005): Radiotherapy plus concomitant and adjuvant temo- zolomide for glioblastoma. N Engl J Med 352: 987–996

    Article  PubMed  Google Scholar 

  • Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schnee- weiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013): Pertuzumab, trastuzu- mab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461–471

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Van Cutsem E, Köhne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011): Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019

    Article  CAS  PubMed  Google Scholar 

  • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007): Open-label phase III trial of panitumum- ab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664

    Article  CAS  PubMed  Google Scholar 

  • Waddell T, Cunningham D (2013): Evaluation of regorafenib in colorectal cancer and GIST. Lancet381: 273–275

    Google Scholar 

  • Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012): Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012 Jul 11; 7: CD00894–1

    Google Scholar 

  • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011): Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. W. Jens Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Zeller, W., Schwabe, U. (2015). Onkologika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_34

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_34

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation